3 Humongous Health-Care Stocks This Week

Sure, the major indexes are all down again this week. Europe's in another recession. Middle East tensions are rising. The U.S. is rolling ahead toward the fiscal cliff.

But not everyone is experiencing such gloom, doom, and misery. We always have some cheerful news in the world of health care. Here are three bright spots from the past week.

To infinity and beyond
Infinity Pharmaceuticals
(Nasdaq: INFI  ) shares skyrocketed by 20% this week. The market was all abuzz after the company announced good results from a phase 1 study of its experimental rheumatoid arthritis drug, IPI-145.

The study found that the drug worked well even with low doses. Importantly, data also showed that IPI-145 was well tolerated. That's good news for the company as it seeks to move forward with a phase 2 study for rheumatoid arthritis. Another phase 2 study for the drug in treating asthma is already under way.

Infinity's hopes don't rest entirely on IPI-145, though. The company also has another drug in phase 2 -- retaspimycin hydrochloride. The drug targets non-small-cell lung cancer and is used in combination with Sanofi's (NYSE: SNY  ) Taxotere. 

Who's in the 100%?
Gilead Sciences
(Nasdaq: GILD  ) announced very good news over last weekend that sent its shares flying high starting at Monday's market open. Shares climbed more than 14% for the week.

The company shared interim data from its ongoing phase 2 study of a combination treatment for the hepatitis C virus. The preliminary results showed that 100% of patients remained free of HCV four weeks after taking a combination of sofosbuvir, NS5A inhibitor GS-5885 and ribavirin.

That's great potential news for patients with HCV. It's really good news for Gilead. However, it's also bad news for competitors such as Achillion Pharmaceuticals (Nasdaq: ACHN  ) . Achillion is also testing an HCV drug, but its results haven't been as spectacular as Gilead's.

Thanksgiving comes early
Sarepta Therapeutics
(Nasdaq: SRPT  ) saw its shares jump nearly 14% this week without even trying. Shareholders might want to send a thank-you note in advance of the Thanksgiving holiday to Liisa Bayko, senior analyst with JMP Securities.

Bayko wrote that GlaxoSmithKline (NYSE: GSK  ) and its partner Prosensa don't expect approval for Duchenne muscular dystrophy drug Dispersen until 2014 at the earliest. That would benefit Sarepta, which has phase 2 studies in progress for eteplirsen. Shares traded higher on Bayko's comments.

Sarepta's results for eteplirsen have been promising so far. A phase 2b extension trial found that patients with Duchenne muscular dystrophy who took eteplirsen achieved significant improvement in the six-minute walk test compared with those taking a placebo. The patients taking eteplirsen also had increased levels of dystrophin, a protein important in preventing damage to muscles.

Don't worry, be happy
Despite the gloomy outlook in general these days for the market, opportunities still exist for investors to find nice returns. While many worried about the dropping Dow and the shrinking S&P 500, those who owned shares in any of the companies mentioned here had reasons to be happy this week. I extend my apologies if you find yourself whistling the Bobby McFerrin tune all weekend.

If you hope to be happily whistling about finances years from now, your best approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2118097, ~/Articles/ArticleHandler.aspx, 10/22/2014 10:22:09 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 hour ago Sponsored by:
DOW 16,461.32 -153.49 -0.92%
S&P 500 1,927.11 -14.17 -0.73%
NASD 4,382.85 -36.63 -0.83%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/22/2014 3:59 PM
GILD $106.09 Down -0.58 -0.54%
Gilead Sciences CAPS Rating: *****
INFI $12.71 Down -0.29 -2.23%
Infinity Pharmaceu… CAPS Rating: **
SRPT $22.29 Down -0.20 -0.89%
Sarepta Therapeuti… CAPS Rating: ***
ACHN $11.06 Down -0.37 -3.24%
ACHILLION PHARMACE… CAPS Rating: **
GSK $44.41 Up +0.78 +1.79%
GlaxoSmithKline CAPS Rating: ****

Advertisement